Introduction: Our hospital is a reference center for the treatment of Recurrent Respiratory Papillomatosis (RRP), receiving patients nationwide. Many patients have extensive and aggressive disease, requiring multiple surgical procedures. Some underwent cidofovir injections, without satisfactory results. Increasing evidence supports the use of bevacizumab for the adjuvant treatment of RRP. On the basis of these evidences, we decided to offer this therapeutic alternative to patients referred to our service.